

Article

Reactions of Trifluorotriacetic Acid Lactone and Hexafluorodehydroacetic Acid with Amines: Synthesis of Trifluoromethylated 4-Pyridones and Aminoenones

Vladislav V. Fedin , Sergey A. Usachev , Dmitrii L. Obydenov  and Vyacheslav Y. Sosnovskikh * 

Institute of Natural Sciences and Mathematics, Ural Federal University, 51 Lenina Ave., 620000 Ekaterinburg, Russia

* Correspondence: vy.sosnovskikh@urfu.ru; Tel.: +7-343-389-9597

Abstract: Dehydroacetic acid and triacetic acid lactone are known to be versatile substrates for the synthesis of a variety of azaheterocycles. However, their fluorinated analogs were poorly described in the literature. In the present work, we have investigated reactions of trifluorotriacetic acid lactone and hexafluorodehydroacetic acid with primary amines, phenylenediamine, and phenylhydrazine. While hexafluorodehydroacetic acid reacted the same way as non-fluorinated analog giving 2,6-bis(trifluoromethyl)-4-pyridones, trifluorotriacetic acid lactone had different regioselectivity of nucleophilic attack compared to the parent structure, and corresponding 3-amino-6,6,6-trifluoro-5-oxohex-3-enamides were formed as the products. In the case of binucleophiles, further cyclization took place, forming corresponding benzodiazepine and pyrazoles. The obtained 2,6-bis(trifluoromethyl)-4-pyridones were able to react with active methylene compounds giving fluorinated merocyanine dyes.

Keywords: 4-hydroxy-2-pyrone; 4-pyridone; aminoenone; trifluoromethylated heterocycles; regioselective reactions



Citation: Fedin, V.V.; Usachev, S.A.; Obydenov, D.L.; Sosnovskikh, V.Y. Reactions of Trifluorotriacetic Acid Lactone and Hexafluorodehydroacetic Acid with Amines: Synthesis of Trifluoromethylated 4-Pyridones and Aminoenones. *Molecules* **2022**, *27*, 7098. <https://doi.org/10.3390/molecules27207098>

Academic Editors: Alexey M. Starosotnikov, Maxim A. Bastrakov and Igor L. Dalinger

Received: 19 September 2022

Accepted: 17 October 2022

Published: 20 October 2022

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Oxygen heterocycles are common precursors in organic synthesis and have a special place in the synthesis of important nitrogen heterocycles by various methodologies. Among others, pyrones attract significant interest both due to a variety of chemical properties and a wide distribution in nature [1–4]. Particular attention is paid to 4-hydroxy-2-pyrones, namely, triacetic acid lactone (TAL), dehydroacetic acid (DHA, Figure 1), and their derivatives, which belong to polyketides and occur widely in living organisms [5–8]. The availability of these compounds and the possibility of their biochemical synthesis contributed to their extensive research and to the development of a wide range of options for their modification, considering them as platform compounds [9–12].

On the other hand, the introduction of fluorine into the structure of molecules often leads to a modification of their chemical properties [13] and is a common strategy in drug design [14–18], pesticides synthesis [19,20], and other areas [21–24]. However, there are very limited data on fluorine-containing analogs of TAL and DHA in the literature, which practically do not cover their properties. The only synthesis of 4-hydroxy-3-trifluoroacetyl-6-trifluoromethyl-2H-pyran-2-one (hexafluorodehydroacetic acid, DHA-*f*₆, Figure 1) was performed by the heating of trifluoroacetoacetic ester in the presence of P₂O₅ and proceeds through formation and dimerization of trifluoroacetylketene [25]. Hydrolysis of DHA-*f*₆ in aqueous NaHCO₃ leads to 4-hydroxy-6-trifluoromethyl-2H-pyran-2-one (trifluorotriacetic acid lactone, TAL-*f*₃, Figure 1) [25]. The second route for the synthesis of TAL-*f*₃ presented in the literature comprises cyclization of the corresponding trifluorodioxocaproic acid with acetic anhydride [26]. Among the properties of TAL-*f*₃, only modification of the 4-OH group is known, which was methylated with Me₂SO₄ [27] and triflated with Tf₂O [26]. The ring-opening of the O-methyl derivative on treatment with magnesium methylate gave

methyl 3-methoxy-5-oxo-6,6,6-trifluoro-5-hexenoate [27] and the 4-OTf derivative reacted with 4-(methylthio)phenylboronic acid to give a Suzuki coupling product [26].





Figure 1. Structure of DHA, TAL, DHA-*f*₆, and TAL-*f*₃.

Thus, compounds that are attractive in terms of reactivity and properties of possible products turned out to be completely unexplored, and in this work, we have studied the interaction of DHA-*f*₆ and TAL-*f*₃ with primary amines as typical nucleophiles.

2. Results and Discussion


To begin with, we reproduced the synthesis described by German et al. (Scheme 1) [25], as it gives access both to DHA-*f*₆ and TAL-*f*₃. The results of the first step were quite inconsistent, and the yield ranged from 0% to 75%, presumably due to heating with a flame burner, which is hard to control. Nevertheless, the product was obtained in a satisfactory quantity for the further research. It should be noted that no variation in reaction conditions has improved the yield. Thus, the lowering of P₂O₅ loading or increasing reaction time resulted in the formation of complex mixtures, either of open-chain condensation products and trimerization ones characterized by the ester methylene quartets in ¹H NMR spectra or triads of equal intensity in ¹⁹F NMR spectra correspondingly. The hydrolysis of DHA-*f*₆ was more reproducible; however, we could never achieve the literature yield of 95% and had 40% on average (Scheme 1). Apart from NaHCO₃, we have used NaOH and Na₂CO₃ as a base, but the yields were slightly lower. Adjusting pH to 4–5 during hydrolysis as the original procedure claims was quite difficult because it dropped down in time due to trifluoroacetic acid formation, so 2.0 equiv. of NaHCO₃ was used instead. Moreover, crystallization of TAL-*f*₃ did not occur until acidification to pH 0–1. We tried, as well, to carry out the detrifluoroacetylation of DHA-*f*₆ by boiling it in water or by treatment with 93% H₂SO₄ or 70% HClO₄ at room temperature, but the conversion was negligible.



Scheme 1. Synthesis of DHA-*f*₆ (1) and TAL-*f*₃ (2).

At the first step, we studied the reaction of DHA-*f*₆ with aniline. There are three main consecutive products that can be expected based on the literature data (Scheme 2) [28,29].

While a formation of Schiff bases usually proceeds readily in acidic media, no conversion was observed when we attempted the synthesis of intermediate **A** in aqueous HCl with 1.5 equiv. of PhNH₂ (Table 1, entry 1). When EtOH was used as a solvent, spontaneous decarboxylation took place and *N*-phenylpyridone **3a** was isolated in 60% yield (Table 1, entry 2). Formation of intermediate **B** was also observed and will be discussed later. Increasing the amount of PhNH₂ and carrying out the reaction in a less polar solvent or without it as well as raising the temperature did not improve the yield (Table 1, entries 3–10).




Scheme 2. Reaction of DHA-*f*₆ with aniline.

Table 1. Optimization of the reaction conditions of DHA-*f*₆ with aniline ^a.

Entry	PhNH ₂ , Equiv.	Solvent	Yield 3a, %
1	1.5	HCl (0.5 M) ^b	n.r. ^c
2	2.3	ethanol	60
3	3.5	ethanol	40
4	4.0	ethanol	45
5	2.3	ethanol	37 ^d
6	4.0	1,4-dioxane	36
7	3.5	1,4-dioxane	27 ^e
8	4.0	toluene	17
9	2.3	toluene	19
10	2.3	neat	25

^a A solution of PhNH₂ in 1 mL of a solvent was added to DHA-*f*₆ (**1**) (100 mg, 0.36 mmol) and the reaction mixture was stirred at room temperature for 24 h. ^b Aqueous solution. ^c No reaction. ^d The reaction was carried out at 65 °C for 12 h. ^e The reaction was carried out at reflux for 4 h.

Exploring the scope of the synthesis of 4-pyridones **3** from DHA-*f*₆, we found that the reaction rates and the yields correlate with nucleophilicity of amine. Thus, aniline derivatives bearing π -donor substituents (MeO, F) at the 4-position react considerably faster, whereas those bearing strong acceptor substituents (Ac, CF₃) at the 3-position or a weak acceptor substituent (Br) at the 4-position react at a comparable rate but give slightly lower yields (Scheme 3, Table 2). Noteworthy, even extremely weakly nucleophilic 4-nitroaniline was able to react although the conversion was low even after 6 days, and pyridone **3k** was formed in only 8% yield. The characteristic signals of pyridones **3** in the NMR spectra acquired in CDCl₃ are the singlet of vinylic CH with double intensity at 6.95–7.02 ppm (¹H NMR) and the quartets of symmetric carbons at 119.2–119.4 ppm (CF₃), 140.8–141.6 ppm (C-2 and C-6), and 119.0–119.6 ppm (C-3 and C-5).



Scheme 3. Reaction of DHA-*f*₆ with aromatic amines.

Table 2. The scope of 4-pyridone synthesis from DHA-*f*₆ ^a.


Pyridone	Ar	Time, h	Yield, %	Mp, °C
3a	Ph	24	60	135–136
3b	4-MeOC ₆ H ₄	8	56	125–126
3c	3,4-F ₂ C ₆ H ₃	6	57	142–143
3d	4-BrC ₆ H ₄	24	47	129–131
3e	3-AcC ₆ H ₄	24	47	118–119
3f	3-F ₃ CC ₆ H ₄	24	47	91–92
3g	2,5-F ₂ C ₆ H ₃	48	46	116–119
3h	2-ClC ₆ H ₄	40	49	132–136
3i	2-MeC ₆ H ₄	24	65	Liq.
3j	2,5-Me ₂ C ₆ H ₃	24	48	105–107
3k	4-O ₂ NC ₆ H ₄	144	8 ^b	– ^c

^a A solution of ArNH₂ (0.83 mmol) in EtOH was added to DHA-*f*₆ (**1**) (100 mg, 0.36 mmol) and the reaction mixture was stirred at room temperature for a given amount of time. ^b Based on ¹H NMR spectrum. ^c The product was obtained in the mixture with 4-nitroaniline.

The existence of an *ortho*-substituent did not affect the initial two steps of the reaction sequence and CO₂ evolution occurred during first 1–2 h; however, the cyclization of bisenamines **B** depends on electron properties of the substituent. In the case of more reactive *o*-toluidine and 2,5-xylidine, the overall duration was 24 h, whereas 2-chloro- and 2,5-difluoroaniline required twice as much time (Table 2). It allowed us to isolate and characterize the intermediate **B'** (Scheme 3), although in the mixture with starting 2-chloroaniline, which did not separate by the column chromatography. Its structure was confirmed by very distinguishable singlets of symmetric groups at 5.78 ppm (vinylic CH) and 11.49 ppm (enaminone NH) in ¹H NMR and at 97.8 ppm in ¹⁹F NMR spectra in CDCl₃. The formation of adducts with the structure of **B** was observed by TLC in all the cases, but for most of them the simultaneous cyclization to pyridones **3** occurred, so their isolation was impractical.

Surprisingly, aliphatic amines such as butylamine, *N,N*-dimethylethylenediamine and benzylamine did not react with DHA-*f*₆ under the conditions found, even after several weeks. It can be attributed to their much higher basicity and fixation of the substrate in an anionic form that prevents further nucleophilic attack. This assumption was supported by the formation of the salt **4** (Scheme 3) in the reaction with 2-aminopyridine, which precipitated in nearly quantitative yield and remained unchanged after 8 days at 60 °C in EtOH. The signals in the ¹⁹F NMR spectrum of compound **4** in DMSO-*d*₆ almost exactly match the signals of DHA-*f*₆ (91.0 and 89.8 ppm compared to 91.1 and 89.6 ppm, respectively) and the singlet of pyrone CH in the ¹H NMR spectrum is shifted upfield by 0.09 ppm (6.15 compared to 6.24 ppm) in agreement with its anionic character.

Reactivity of 4-pyridones **3** is greatly affected by strongly acceptor CF_3 -groups. Thus, electrophilic bromination of **3a** with NBS proceeded poorly compared to the non-fluorinated analog [30] and no distinct product was obtained. On the contrary, Knoevenagel condensation did well with malononitrile, barbituric acid, and indane-1,3-dione in acetic anhydride, leading to fluorinated merocyanine dyes **5** (Scheme 4, Table 3). This reveals that the electron deficiency of a heterocycle plays an important role for this reaction, as 1-aryl-2,6-dimethyl-4-pyridones are less active [31,32] compared both to the CF_3 -substituted pyridone **3a** and to the oxygen analog, 2,6-dimethyl-4-pyrone [33]. The time required for the reaction completion is in accordance with the acidity of an active methylene compound, so one can assume that deprotonation is a rate-limiting step, and a high activity of a substrate is necessary to prevent self-condensation of CH_2X_2 .



Scheme 4. Reaction of 4-pyridone **3a** with active methylene compounds.

Table 3. Synthesis and structure of adducts **5a–c** ^a.

Compound	Structure	Time, h	Yield, %	Mp, °C
5a		10	65	172–173
5b		4	58	270–271
5c		6	43	208–209

^a A solution of 4-pyridone **3a** (100 mg, 0.33 mmol) and the corresponding CH_2X_2 (0.4 mmol) in Ac_2O was stirred at 140 °C for a given amount of time.

The prepared compounds, **5a–c**, are found to be yellow solids and exhibit an absorbance major maximum at 382–437 nm in the visible region of the spectra. For barbituric derivative **5b**, the high molar extinction coefficient ($91406 \text{ M}^{-1}\cdot\text{cm}^{-1}$ at 412 nm) is observed and probably indicates the intramolecular charge-transfer described by the aromatic resonance form **5'** (Figure 2). For dihydropyridine **5c** bearing the indanedione moiety, additional intensive absorption maxima are observed at 246 and 224 nm. An interesting feature in NMR spectra of compounds **5** is a large difference compared to each other in chemical shifts of CH-groups in the dihydropyridine fragment attributed to the magnetic anisotropy of carbonyl and cyano groups, which have a closer proximity in derivative **5b** ($\delta_{\text{H}3} = 9.77 \text{ ppm}$, $\delta_{\text{C}3} = 116.8 \text{ ppm}$) than in **5c** ($\delta_{\text{H}3} = 9.10 \text{ ppm}$, $\delta_{\text{C}3} = 113.4 \text{ ppm}$) and in **5a** ($\delta_{\text{H}3} = 7.26 \text{ ppm}$, $\delta_{\text{C}3} = 112.7 \text{ ppm}$). Another possible explanation for the difference is a greater contribution of the betaine resonance form **5'** (Figure 2) for the adduct with barbituric acid, but this seems to have a smaller effect as the chemical shifts of the rest of carbon atoms diverge much less (Table S2 in Supplementary Materials).






Figure 2. Resonance forms of compound 5.

Moving on to the investigation of trifluorotriacetic acid lactone (**2**) properties, we focused on our previous work on the study of triacetic acid lactone (**6**) [34] and 2-cyano-6-(trifluoromethyl)-4*H*-pyran-4-one (**7**) [35], which gave carbamoylated enaminones **8** (Scheme 5), which proved to be a versatile building blocks for nitrogen heterocycles. In both cases, the substrates were attacked with two equivalents of amine at positions 2 and 6.



Scheme 5. Reaction of TAL and 2-cyano-6-(trifluoromethyl)-4-pyrone with primary amines.

We started the optimization of the reaction conditions of TAL-*f*₃ (**2**) with aniline in EtOH using various amount of amine (Scheme 6, Table 4, entries 1–3). The product **9a** with unexpected regiochemistry was formed with the best yield of 64% when only little excess of PhNH₂ was applied. The reaction performs better in aprotic polar 1,4-dioxane (Table 4, entry 4) and worse in non-polar toluene or without a solvent (Table 4; entries 5, 6). It should be noted that an increase in the reaction temperature did not improve the yield of enaminone **9a**.




Scheme 6. Reaction of TAL-*f*₃ with aniline.

Table 4. Optimization of the reaction conditions of TAL-*f*₃ with aniline ^a.

Entry	PhNH ₂ , Equiv.	Solvent	Yield 9a , %
1	5	ethanol	43
2	3.5	ethanol	63
3	2.1	ethanol	64
4	2.1	1,4-dioxane	72
5	2.1	toluene	30
6	2.1	neat	12

^a A solution of PhNH₂ was added to TAL-*f*₃ (**2**) (100 mg, 0.56 mmol). The reaction mixture was stirred at room temperature for 24 h.

The reaction with electron-rich *p*-anisidine proceeded equally well, whereas electron-poor *p*-bromoaniline gave lower yield (Scheme 7, Table 5). The reaction with aliphatic amines again has difficulties, probably due to the formation of salts; however, the lower acidity of TAL-*f*₃ compared to DHA-*f*₆ allowed enaminones **9d,e** to form in low yields. In the case of butylamine, the heating to 60 °C was also needed. All amines reacted with the same regioselectivity, and no alternative isomers **8** were isolated.



Scheme 7. Reaction of TAL-*f*₃ with primary amines.

Table 5. The scope of reaction of TAL-*f*₃ with primary amines ^a.

Enaminone	R	Time, h	Yield, %	Z/E ratio ^b
9a	Ph	24	72	59:41 (44:56 °)
9b	4-MeOC ₆ H ₄	17	69	65:35
9c	4-BrC ₆ H ₄	15	41	59:41
9d	Bn	17	24	58:42 (67:33 °)
9e	Bu	72	7 ^d	65:35

^a A solution of RNH₂ (1.17 mmol) in 1,4-dioxane was added to TAL-*f*₃ (**2**) (100 mg, 0.56 mmol). The reaction mixture was stirred at room temperature for a given amount of time. ^b Assessed by ¹H and ¹⁹F NMR in CDCl₃. ^c Assessed by ¹H and ¹⁹F NMR in DMSO-*d*₆. ^d The reaction was carried out at 60 °C.

Although Z-form of enaminones is predominant because of an effective intramolecular hydrogen bonding, the contribution of an *E*-isomer may be affected by the electronic nature of a substituent at a nitrogen atom [36] or by an alternative hydrogen bond formation [37], which is the case for product **9** (Figure 3). The ratio of isomers is solvent-dependent, and Z-form mostly prevails, except for compound **4a** in DMSO-*d*₆ (Table 5). The assignment of isomers was conducted on the basis of ¹H and ¹³C NMR spectra (Table S3 in Supplementary Materials). The key signals are low-field NH-protons of Z-**9** isomers at 12.39–12.58 ppm (for N-arylenaminones **9a–c** in CDCl₃) and at 11.08–11.32 ppm (for N-alkylenaminones **9d,e** in CDCl₃). The corresponding signals for the *E*-isomers of **9** are under a much higher field in accordance with the literature [37,38]. Among the other features of the NMR spectra of compounds **9** is the existence of methylene protons and amide NH-protons at a lower field and methyne carbons at a higher field for the *E*-isomer (Figure 3).





Figure 3. Equilibrium between Z- and *E*-isomers of enaminones **9** and their characteristic chemical shifts in ¹H (in green) and ¹³C (in magenta) NMR in CDCl₃.


For an explanation of the difference in the regioselectivity of the interaction of TAL and TAL-*f*₃ with amines, we propose the following mechanism. The addition of the first equivalent of RNH₂ leads to the formation of dioxoamide **C** (Scheme 8), which was isolated earlier (X = H) [39]. The intermediate **C** is then attacked by the second amine molecule at the less hindered atom, C-5, in the case of X = H forming product **8**. A preference of the attack at C-3 for the fluorinated derivative may be attributed to a high content of cyclic

form **D** (Scheme 8), analogs of which were described in the literature as the only tautomer in CDCl_3 and $\text{DMSO-}d_6$ solutions [40,41]. The semiaminal carbon atom is less susceptible to nucleophiles than the free keto group that leads to the selective formation of product **9**. It also should be noted that a mixture of regioisomers is usually produced when linear aliphatic CF_3 -diketones react with aniline [42].




Scheme 8. Proposed mechanism of the reaction of TAL and TAL- f_3 with primary amines.

No change in selectivity was observed when bifunctional aromatic amine, *o*-phenylenediamine, was used in the optimized conditions. Benzodiazepinone **10** was formed as the only isolated product, although the yield was moderate (Scheme 9). Compound **10** was previously obtained from the corresponding dioxoester **11** in the mixture with diazepine **12** [43] (Scheme 9), so our method represents a good alternative with no specific separation needed.



Scheme 9. Reaction of TAL- f_3 and ethyl 6,6,6-trifluoro-3,5-dioxohexanoate with *o*-phenylenediamine.

Phenylhydrazine also reacted with TAL- f_3 (**2**) regioselectively in 1,4-dioxane, giving pyrazolohydrazide **13**, but the yield was poor. Changing the solvent to EtOH substantially increased the outcome, though isomer **14** was also formed and did not separate by the column chromatography (Scheme 10). Compound **14** was previously synthesized from cyanopyrone **7** [35] and its spectral characteristics are in a good correlation with our data. Both isomers appear as two sets of signals corresponding to a major *syn*- (presented at Scheme 10) and a minor *anti*-rotamer about the N–N bond. The key differences in the NMR spectra of the regioisomer **13** are the more downfield signal of the CF_3 group in ^{19}F NMR (106.2 ppm compared to 101.9 ppm for **14**) due to deshielding from the adjacent phenyl substituent, and more downfield signals of NH groups in ^1H NMR (9.91 and 7.82 ppm compared to 9.84 and 7.73 ppm for **14**) due to additional hydrogen bonding.



Scheme 10. Reaction of TAL-*f*₃ with phenylhydrazine.

Thus, hexafluorodehydroacetic acid and trifluorotriacetic acid lactone were shown to be active electrophiles and represent interesting fluorinated building blocks, which were transformed to a number of nitrogen heterocycles. Reaction of hexafluorodehydroacetic acid with primary aromatic amines leads to the formation of 2,6-bis(trifluoromethyl)-4-pyridones that are able to undergo Knoevenagel condensation to give merocyanine dyes. Trifluorotriacetic acid lactone undergoes ring-opening transformations with mono- and binucleophilic primary amines at the positions 2 and 4 and differs in regioselectivity compared to the non-fluorinated analog.

3. Materials and Methods

NMR spectra were recorded on Bruker DRX-400 (Bruker BioSpin GmbH, Ettlingen, Germany, work frequencies: ¹H–400 MHz, ¹³C–100 MHz, ¹⁹F–376.5 MHz) and Bruker Avance III-500 (Bruker BioSpin GmbH, Rheinstetten, Germany, work frequencies: ¹H–500 MHz, ¹³C–126 MHz, ¹⁹F–471 MHz) spectrometers in DMSO-*d*₆ and CDCl₃. The chemical shifts (δ) are reported in ppm relative to the internal standard TMS (¹H NMR), C₆F₆ (¹⁹F NMR), and residual signals of the solvents (¹³C NMR). IR spectra were recorded on a Shimadzu IRSpirit-T spectrometer (Shimadzu Corp., Kyoto, Japan) using an attenuated total reflectance (ATR) unit (FTIR mode, ZnSe crystal), and the absorbance maxima (ν) are reported in cm⁻¹. UV-visible spectra were recorded on a Shimadzu UV-1900 spectrophotometer (Shimadzu Corp., Kyoto, Japan) using EtOH as a solvent, the absorbance maxima (λ) are reported in nm, and the molar attenuation coefficients are reported in L·mol⁻¹·cm⁻¹. Elemental analyses were performed on an automatic analyzer PerkinElmer PE 2400 Series II (Perkin Elmer Instruments, Waltham, MA, USA). Melting points were determined using a Stuart SMP40 melting point apparatus (Bibby Scientific Ltd., Stone, Staffordshire, UK). Column chromatography was performed on silica gel (Merck 60, 70–230 mesh). All solvents and reagents were obtained commercially and used without purification.

3.1. Synthesis of Pyrones **1** and **2**

4-Hydroxy-3-(2,2,2-trifluoroacetyl)-6-(trifluoromethyl)-2H-pyran-2-one (1). A mixture of ethyl 4,4,4-trifluoroacetoacetate (9.1 g, 0.032 mol) and P₂O₅ (40 g, 0.141 mol) was heated with a gas burner flame for 10 min. Then, the mixture was distilled in a vacuum (~20 torr), collecting the fraction 90–110 °C. The target fraction was redistilled in the same interval. Yield 4.1 g (75%), yellowish needles, mp 40–42 °C. ¹H NMR (500 MHz, DMSO-*d*₆) δ 6.24 (1H, s, H-5), 11.12 (1H, s, OH). ¹⁹F NMR (471 MHz, DMSO-*d*₆) δ 89.6 (s, COCF₃), 91.1 (s, 6-CF₃) [25].

4-Hydroxy-6-(trifluoromethyl)-2H-pyran-2-one (2). A saturated aqueous solution of NaHCO₃ (0.5 mL, 0.55 mmol) was added with stirring to an aqueous solution of hexafluorodehydroacetic acid (**1**) (2.5 mL, 1 M). The mixture was stirred for 10 min and acidified with aqueous HCl (1 mL, 3 M). The precipitate was filtered off and dried. Yield 180 mg (40%), white solid, mp 135–138 °C (lit. mp 135–137 °C [25]). ¹H NMR (500 MHz, DMSO-*d*₆) δ 5.59 (1H, d, *J* = 1.8 Hz, H-3), 6.83 (1H, d, *J* = 1.7 Hz, H-5), 12.60 (1H, s, OH). ¹⁹F NMR (471 MHz, DMSO-*d*₆) δ 92.0 (s, CF₃).

3.2. Synthesis of Compounds **3a–k**

General Procedure

An aromatic amine (0.83 mmol) was added to a solution of hexafluorodehydroacetic acid (**1**) (100 mg, 0.36 mmol) in EtOH (1 mL). The reaction mixture was stirred at room

temperature for a given amount of time and acidified with aqueous HCl (3 mL, 1 M). The precipitate was filtered off and washed with water. The crude product was recrystallized from hexane.

1-Phenyl-2,6-bis(trifluoromethyl)pyridin-4(1H)-one (3a). The reaction was carried out for 24 h. Yield 66 mg (60%), yellow powder, mp 135–136 °C. ^1H NMR (400 MHz, CDCl_3) δ 6.97 (2H, s, H-3, H-5), 7.39 (2H, d, $J = 7.6$ Hz, H Ph), 7.50 (2H, t, $J = 7.9$ Hz, H Ph), 7.59 (1H, t, $J = 7.5$ Hz, H Ph). ^1H NMR (500 MHz, $\text{DMSO-}d_6$) δ 6.97 (2H, s, H-3, H-5), 7.55 (2H, t, $J = 7.7$ Hz, H Ph), 7.59 (1H, t, $J = 7.5$ Hz, H Ph), 7.70 (2H, d, $J = 7.8$ Hz, H Ph). ^{19}F NMR (471 MHz, CDCl_3) δ 100.6 (s, CF_3). ^{19}F NMR (471 MHz, $\text{DMSO-}d_6$) δ 102.5 (s, CF_3). ^{13}C NMR (126 MHz, CDCl_3) δ 119.1 (2C, q, $J = 4.7$ Hz, C-3, C-5), 119.4 (2C, q, $J = 275.7$ Hz, CF_3), 128.7 (2C Ph), 130.1 (2C Ph), 131.3 (C Ph), 135.0 (C Ph), 141.2 (2C, q, $J = 33.3$ Hz, C-2, C-6), 177.4 (CO). IR (ATR) ν 3297, 1700 (C=O), 1658, 1398 (N–C), 1128–1116 (CF_3). Anal. Calculated for $\text{C}_{13}\text{H}_7\text{F}_6\text{NO}$: C 50.83; H 2.30; N 4.56. Found: C 50.77; H 2.38; N 4.46.

1-(4-Methoxyphenyl)-2,6-bis(trifluoromethyl)pyridin-4(1H)-one (3b). The reaction was carried out for 8 h. Yield 68 mg (56%), gray powder, mp 125–126 °C. ^1H NMR (400 MHz, CDCl_3) δ 3.88 (3H, s, CH_3), 6.95 (2H, s, H-3, H-5), 6.95 (2H, d, $J = 8.9$ Hz, H Ar), 7.28 (2H, d, $J = 8.9$ Hz, H Ar). ^{19}F NMR (471 MHz, CDCl_3) δ 100.5 (s, CF_3). ^{13}C NMR (126 MHz, CDCl_3) δ 55.6 (OCH_3), 113.7 (2C Ar), 119.1 (2C, q, $J = 4.7$ Hz, C-3, C-5), 119.4 (2C, q, $J = 275.6$ Hz, CF_3), 127.2 (C Ar), 131.2 (2C Ar), 141.6 (2C, q, $J = 32.7$ Hz, C-2, C-6), 161.3 (C Ar), 177.5 (CO). IR (ATR) ν 3061, 1653 (C=O), 1602, 1510, 1397 (N–C), 1250, 1397, 1158 (CF_3). HRMS (ESI) m/z $[\text{M} + \text{H}]^+$. Calculated for $\text{C}_{14}\text{H}_{10}\text{F}_6\text{NO}_2$: 338.0616. Found: 338.0613.

1-(3,4-Difluorophenyl)-2,6-bis(trifluoromethyl)pyridin-4(1H)-one (3c). The reaction was carried out for 6 h. Yield 71 mg (57%), gray powder, mp 142–143 °C. ^1H NMR (500 MHz, CDCl_3) δ 6.96 (2H, s, H-3, H-5), 7.21 (1H, d, $J = 8.6$ Hz, H Ar), 7.31 (2H, m, H Ar). ^{19}F NMR (471 MHz, CDCl_3) δ 28.3 (1F, dt, $J = 21.3, 8.8$ Hz, F Ar), 31.0 (1F, dddd, $J = 21.3, 9.5, 6.7, 3.8$ Hz, F Ar), 100.7 (6F, s, CF_3). ^{13}C NMR (101 MHz, CDCl_3) δ 117.4 (d, $J = 18.9$ Hz, C Ar), 119.3 (2C, q, $J = 275.7$ Hz, CF_3), 119.4 (2C, q, $J = 4.7$ Hz, C-3, C-5), 120.2 (d, $J = 19.1$ Hz, C Ar), 127.3 (C Ar), 130.6 (C Ar), 140.9 (2C, q, $J = 33.3$ Hz, C-2, C-6), 149.5 (dd, $J = 254.1, 13.8$ Hz, C Ar), 152.1 (dd, $J = 256.4, 12.2$ Hz, C Ar), 177.1 (CO). IR (ATR) ν 3091, 3056, 1655 (C=O), 1615, 1519, 1397 (N–C), 1144 (CF_3). Anal. Calculated for $\text{C}_{13}\text{H}_5\text{F}_8\text{NO}$: C 45.50; H 1.47; N 4.08. Found: C 45.33; H 1.46; N 4.09.

1-(4-Bromophenyl)-2,6-bis(trifluoromethyl)pyridin-4(1H)-one (3d). The reaction was carried out for 24 h. Yield 65 mg (47%), yellow powder, mp 129–131 °C (decomp.). ^1H NMR (400 MHz, CDCl_3) δ 6.97 (2H, s, H-3, H-5), 7.27 (2H, d, $J = 8.1$ Hz, H Ar), 7.64 (1H, d, $J = 8.5$ Hz, H Ar). ^{19}F NMR (471 MHz, CDCl_3) δ 100.7 (s, CF_3). ^{13}C NMR (101 MHz, CDCl_3) δ 119.26 (2C, q, $J = 4.5$ Hz, C-3, C-5), 119.33 (2C, q, $J = 275.8$ Hz, CF_3), 126.0 (C Ar), 131.7 (2C, C Ar), 132.1 (2C, C Ar), 133.9 (C Ar), 141.0 (2C, q, $J = 32.8$ Hz, C-2, C-6), 177.3 (CO). IR (ATR) ν 3071, 1652 (C=O), 1589, 1480, 1397 (N–C), 1249, 1175 (CF_3). HRMS (ESI) m/z $[\text{M} + \text{H}]^+$. Calculated for $\text{C}_{13}\text{H}_7\text{BrF}_6\text{NO}$: 385.9615. Found: 385.9606.

1-(3-Acetylphenyl)-2,6-bis(trifluoromethyl)pyridin-4(1H)-one (3e). The reaction was carried out for 24 h. Yield 60 mg (47%), pale pink powder, mp 118–119 °C. ^1H NMR (400 MHz, CDCl_3) δ 2.65 (3H, s, CH_3), 6.99 (2H, s, H-3, H-5), 7.57–7.69 (2H, m, H Ar), 8.00 (1H, s, H Ar), 8.17 (1H, dt, $J = 7.4, 1.5$ Hz, H Ar). ^{19}F NMR (376 MHz, CDCl_3) δ 100.8 (s, CF_3). ^{13}C NMR (126 MHz, CDCl_3) δ 26.6 (CH_3), 119.0 (2C, unres. q, C-3, C-5), 119.2 (2C, q, $J = 276.1$ Hz, CF_3), 129.2 (C Ar), 129.8 (C Ar), 131.2 (C Ar), 134.1 (C Ar), 135.4 (C Ar), 137.7 (C Ar), 141.6 (2C, unres. q, C-2, C-6), 177.2 (4-CO), 195.6 (COCH_3). IR (ATR) ν 3068, 1700 (C=O), 1665 (C=O), 1610, 1480, 1402 (N–C), 1138 (CF_3). Anal. Calculated for $\text{C}_{15}\text{H}_9\text{F}_6\text{NO}_2$: C 51.59; H 2.60; N 4.01. Found: C 51.50; H 2.63; N 3.99.

1-(3-(Trifluoromethyl)phenyl)-2,6-bis(trifluoromethyl)pyridin-4(1H)-one (3f). The reaction was carried out for 24 h. Yield 63 mg (47%), light-yellow powder, mp 91–92 °C. ^1H NMR (600 MHz, CDCl_3) δ 7.00 (2H, s, H-3, H-5), 7.64 (1H, d, $J = 8.2$ Hz, H Ar), 7.69 (1H, t, $J = 8.0$ Hz, H Ar), 7.72 (1H, s, H Ar), 7.89 (1H, d, $J = 7.8$ Hz, H Ar). ^{19}F NMR (376 MHz, CDCl_3) δ 98.7 (3F, s, CF_3 Ar), 100.7 (6F, s, 2- CF_3 , 6- CF_3). ^{13}C NMR (126 MHz, CDCl_3) δ 119.3 (2C, q, $J = 275.5$ Hz, 2- CF_3 , 6- CF_3), 119.4 (2C, q, $J = 4.7$ Hz, C-3, C-5), 122.9 (q, $J = 272.5$ Hz,

CF₃ Ar), 127.6 (C Ar), 128.3 (C Ar), 129.6 (C Ar), 131.8 (q, *J* = 33.8 Hz, C-3 Ar), 133.6 (C Ar), 135.4 (C Ar), 140.9 (2C, q, *J* = 33.4 Hz, C-2, C-6), 177.2 (CO). IR (ATR) ν 3091, 1655 (C=O), 1395 (N–C), 1327, 1252, 1126 (CF₃). HRMS (ESI) *m/z* [M + H]⁺. Calculated for C₁₄H₇F₉NO: 376.0384. Found: 376.0397.

1-(2,5-Difluorophenyl)-2,6-bis(trifluoromethyl)pyridin-4(1H)-one (3g). The reaction was carried out for 48 h. Yield 58 mg (46%), yellow powder, mp 116–119 °C. ¹H NMR (500 MHz, CDCl₃) δ 6.99 (2H, s, H-3, H-5), 7.20–7.26 (2H, m, H-3, H-6 Ar), 7.35 (1H, dddd, *J* = 9.3, 7.4, 3.8, 3.0 Hz, H-4 Ar). ¹⁹F NMR (376 MHz, CDCl₃) δ 38.6–38.8 (m, F-2 Ar), 46.0 (1F, dtd, *J* = 15.4, 7.4, 4.7 Hz, F-5 Ar), 98.5 (dd, *J* = 3.2, 0.9 Hz, CF₃). ¹³C NMR (126 MHz, CDCl₃) δ 117.1 (dd, *J* = 22.4, 8.8 Hz, C Ar), 119.1 (d, *J* = 25.9 Hz, C Ar), 119.3 (2C, q, *J* = 275.5 Hz, CF₃), 119.5 (2C, q, *J* = 4.6 Hz, C-3, C-5), 120.8 (dd, *J* = 23.6, 8.1 Hz, C Ar), 123.4 (dd, *J* = 16.3, 10.5 Hz, C Ar), 140.8 (2C, q, *J* = 34.1 Hz, C-2, C-6), 155.9 (dd, *J* = 252.0, 3.3 Hz, C Ar), 157.4 (dd, *J* = 247.8, 2.8 Hz, C Ar), 177.2 (CO). IR (ATR) ν 3072, 1666 (C=O), 1615, 1508, 1397 (N–C), 1251, 1136 (CF₃). HRMS (ESI) *m/z* [M + H]⁺. Calculated for C₁₃H₆F₈NO: 344.0322. Found: 344.0316.

1-(2-Chlorophenyl)-2,6-bis(trifluoromethyl)pyridin-4(1H)-one (3h). The reaction was carried out for 40 h. Yield is 61 mg (49%), yellow powder, mp 132–136 °C. ¹H NMR (500 MHz, CDCl₃) δ 6.99 (2H, s, H-3, H-5), 7.41–7.48 (1H, m, H Ar), 7.51–7.58 (3H, m, H Ar). ¹⁹F NMR (471 MHz, CDCl₃) δ 98.6 (s, CF₃). ¹³C NMR (126 MHz, CDCl₃) δ 119.3 (2C, q, *J* = 275.8 Hz, CF₃), 119.6 (2C, q, *J* = 4.5 Hz, C-3, C-5), 127.2 (C Ar), 130.1 (C Ar), 131.9 (C Ar), 132.7 (C Ar), 132.9 (C Ar), 135.9 (C Ar), 140.9 (2C, q, *J* = 33.9 Hz, C-2, C-6), 177.6 (CO). IR (ATR) ν 3056, 1743, 1651 (C=O), 1476, 1389 (N–C), 1247, 1136 (CF₃). HRMS (ESI) *m/z* [M + H]⁺. Calculated for C₁₃H₇ClF₆NO: 342.0120. Found: 342.0131.

1-(*o*-Tolyl)-2,6-bis(trifluoromethyl)pyridin-4(1H)-one (3i). The reaction was carried out for 24 h. Yield 74 mg (65%), brown viscous liquid. ¹H NMR (400 MHz, CDCl₃) δ 2.08 (3H, s, CH₃), 7.01 (2H, s, H-3, H-5), 7.35–7.30 (3H, m, H Ar), 7.47 (1H, td, *J* = 7.5, 1.6 Hz, H Ar). ¹⁹F NMR (471 MHz, CDCl₃) δ 99.0 (d, *J* = 1.0 Hz, CF₃). ¹³C NMR (151 MHz, CDCl₃) δ 17.0 (CH₃), 119.3 (2C, q, *J* = 275.8 Hz, CF₃), 119.6 (2C, q, *J* = 4.2 Hz, C-3, C-5), 126.2 (C Ar), 130.3 (C Ar), 130.7 (C Ar), 131.5 (C Ar), 134.1 (C Ar), 138.5 (C Ar), 141.3 (2C, q, *J* = 33.2 Hz, C-2, C-6), 177.9 (CO). IR (ATR) ν 3054, 1696 (C=O), 1620, 1508, 1391 (N–C), 1252, 1135 (CF₃). HRMS (ESI) *m/z* [M + H]⁺. Calculated for C₁₄H₁₀F₆NO: 322.0667. Found: 322.0679.

1-(2,5-Dimethylphenyl)-2,6-bis(trifluoromethyl)pyridin-4(1H)-one (3j). The reaction was carried out for 24 h. Yield 58 mg (48%), brown viscous liquid, crystallizes on standing, mp 105–107 °C. ¹H NMR (500 MHz, CDCl₃) δ 2.02 (3H, s, CH₃), 2.38 (3H, s, CH₃), 7.01 (2H, s, H-3, H-5), 7.16 (1H, s, H-2 Ar), 7.18 (1H, d, *J* = 7.7 Hz, H-5 Ar), 7.27 (1H, d, *J* = 7.7 Hz, H-4 Ar). ¹⁹F NMR (471 MHz, CDCl₃) δ 99.0 (s, CF₃). ¹³C NMR (126 MHz, CDCl₃) δ 16.6 (CH₃), 20.6 (CH₃), 119.3 (2C, q, *J* = 275.8 Hz, CF₃), 119.5 (2C, q, *J* = 4.8 Hz, C-3, C-5), 130.3 (C Ar), 130.6 (C Ar), 132.2 (C Ar), 133.9 (C Ar), 135.2 (C Ar), 136.2 (C Ar), 141.1 (2C, q, *J* = 33.4 Hz, C-2, C-6), 177.5 (CO). IR (ATR) ν 3091, 1655 (C=O), 1608, 1395 (N–C), 1328, 1251, 1125 (CF₃). HRMS (ESI) *m/z* [M + H]⁺. Calculated for C₁₅H₁₂F₆NO: 336.0823. Found: 336.0802.

1-(4-Nitrophenyl)-2,6-bis(trifluoromethyl)pyridin-4(1H)-one (3k). The reaction was carried out for 6 d. Pale yellow powder, a mixture of **3k** (10 mg, 8%) and 4-nitroaniline (32 mg). ¹H NMR (500 MHz, CDCl₃) δ 7.00 (2H, s, H-3, H-5), 7.64 (2H, d, *J* = 8.4 Hz, H Ar), 8.39 (2H, d, *J* = 8.9 Hz, H Ar). ¹⁹F NMR (471 MHz, CDCl₃) δ 100.9 (s, CF₃). HRMS (ESI) *m/z* [M + H]⁺. Calculated for C₁₃H₇F₆N₂O₃: 353.0361. Found: 353.0357.

3.3. Synthesis of Compound B'

o-Chloroaniline (106 mg, 0.83 mmol) was added to a solution of hexafluorodehydroacetic acid (**1**) (100 mg, 0.36 mmol) in EtOH (1 mL). The reaction mixture was stirred at room temperature for a 15 h and acidified with aqueous HCl (3 mL, 1 M). The precipitate was filtered off and washed with water. The crude product was purified by column chromatography (CHCl₃).

(2*Z*,5*Z*)-2,6-Bis((2-chlorophenyl)amino)-1,1,1,7,7,7-hexafluorohepta-2,5-dien-4-one (**B'**). Dark-yellow solid, a mixture of **B'** (108 mg, 64%) and 2-chloroaniline (11 mg), mp 84–85 °C. ¹H

NMR (400 MHz, CDCl₃) δ 5.78 (2H, s, 3-CH, 5-CH), 7.18–7.29 (4H, m, H Ar), 7.33 (2H, d, J = 7.3 Hz, H Ar), 7.44 (2H, dd, J = 7.8, 1.5 Hz, H Ar), 11.49 (2H, s, NH). ¹⁹F NMR (376 MHz, CDCl₃) δ 97.8 (s, CF₃).

3.4. Synthesis of Compound 4

2-Aminopyridine (78 mg, 0.83 mmol) was added to a solution of hexafluorodehydroacetic acid (1) (100 mg, 0.36 mmol) in EtOH (1 mL). The precipitate was filtered and washed with a small amount of EtOH.

2-Aminopyridin-1-ium 2-oxo-3-(2,2,2-trifluoroacetyl)-6-(trifluoromethyl)-2H-pyran-4-olate (4). Yield 127 mg (95%), white solid, mp 205–206 °C. ¹H NMR (400 MHz, DMSO-*d*₆) δ 6.15 (1H, s, H-5 pyrone), 6.86 (1H, td, J = 6.8, 1.0 Hz, H-5 pyridine), 6.97 (1H, dd, J = 9.6, 1.0 Hz, H-3 pyridine), 7.92 (4H, m, NH₂, H-4, H-6 pyridine), 13.27 (1H, s, NH). ¹⁹F NMR (376 MHz, DMSO-*d*₆) δ 89.8 (s, COCF₃), 91.1 (s, CF₃). ¹³C NMR (126 MHz, DMSO-*d*₆) δ 98.4 (C-3), 109.7 (q, J = 2.9 Hz, C-5), 112.1 (C Py), 113.4 (C Py), 116.6 (q, J = 292.1 Hz, CF₃), 118.9 (q, J = 272.8 Hz, CF₃), 136.0 (C Py), 144.1 (C Py), 146.8 (q, J = 37.1 Hz, C-6), 153.9 (C Py), 160.0 (C-2), 176.8 (C-4), 177.7 (q, J = 33.5 Hz, COCF₃). IR (ATR) ν 3366, 3310, 3191, 1712 (C=O), 1699 (C=O), 1535, 1372 (N–C), 1134 (CF₃). Anal. Calculated for C₁₃H₈F₆N₂O₄: C 42.18; H 2.18; N 7.57. Found: C 42.28; H 2.07; N 7.57.

3.5. Synthesis of Compounds 5

General Procedure

A mixture of 1-phenyl-2,6-bis(trifluoromethyl)pyridin-4(1H)-one (100 mg, 0.33 mmol) and a corresponding active methylene compound (0.4 mmol) in Ac₂O (1.5 mL) was heated at 140 °C for a given amount of time. The reaction mixture was then cooled and left overnight for crystallization of a product. The precipitate was filtered and washed with EtOH (1 mL). The product was dried at 120 °C for 4 h.

2-(1-Phenyl-2,6-bis(trifluoromethyl)pyridin-4(1H)-ylidene)malononitrile (5a). Synthesized from malononitrile (10 h). Yield 77 mg (65%). Dark-yellow crystals, mp 172–173 °C. ¹H NMR (500 MHz, DMSO-*d*₆) δ 7.26 (2H, s, H-3', H-5'), 7.59 (2H, t, J = 7.8 Hz, H Ph), 7.66 (1H, t, J = 7.6 Hz, H Ph), 7.74 (2H, d, J = 7.8 Hz, H Ph). ¹⁹F NMR (471 MHz, DMSO-*d*₆) δ 102.5 (s, CF₃). ¹³C NMR (126 MHz, DMSO-*d*₆) δ 57.1 (C(CN)₂), 112.7 (2C, q, J = 5.3 Hz, C-3', C-5'), 114.8 (2C, CN), 118.7 (2C, q, J = 275.9 Hz, CF₃), 128.7 (2C Ph), 130.1 (2C Ph), 131.7 (C Ph), 134.6 (C Ph), 138.2 (2C, q, J = 33.0 Hz, C-2', C-6'), 154.2 (C-4'). IR (ATR) ν 3058, 2922, 2852, 2215, 1643, 1518, 1302 (N–C), 1275, 1142 (CF₃). UV/vis (EtOH): λ_{\max} (ϵ_{\max}) = 382 (18222). HRMS (ESI) m/z [M + H]⁺. Calculated for C₁₆H₈F₆N₃: 356.0622. Found: 356.0624.

5-(1-Phenyl-2,6-bis(trifluoromethyl)pyridin-4(1H)-ylidene)pyrimidine-2,4,6(1H,3H,5H)-trione (5b). Synthesized from barbituric acid (4 h). Yield 81 mg (58%). Dark-yellow powder, mp 270–271 °C (decomp.). ¹H NMR (500 MHz, DMSO-*d*₆) δ 7.59 (2H, t, J = 7.7 Hz, H Ph), 7.66 (1H, t, J = 7.5 Hz, H Ph), 7.80 (2H, d, J = 7.9 Hz, H Ph), 9.77 (2H, s, H-3', H-5'), 10.78 (2H, s, NH). ¹⁹F NMR (471 MHz, DMSO-*d*₆) δ 103.2 (s, CF₃). ¹³C NMR (151 MHz, DMSO-*d*₆) δ 95.0 (C-5), 116.8 (2C, q, J = 5.7 Hz, C-3', C-5'), 119.8 (2C, q, J = 275.5 Hz, CF₃), 129.0 (2C Ph), 130.4 (2C Ph), 132.1 (C Ph), 135.6 (C Ph), 138.3 (2C, q, J = 32.3 Hz, C-2', C-5'), 150.1 (2-CO), 153.0 (C-4'), 165.6 (2C, 4-CO, 6-CO). IR (ATR) ν 3021, 1712, 1673, 1483, 1354 (N–C), 1145 (CF₃). UV/vis (EtOH): λ_{\max} (ϵ_{\max}) = 412 (91406), 234 (37760). HRMS (ESI) m/z [M + H]⁺. Calculated for C₁₇H₁₀F₆N₃O₃: 418.0626. Found: 418.0591.

2-(1-Phenyl-2,6-bis(trifluoromethyl)pyridin-4(1H)-ylidene)1,3-indandione (5c). Synthesized from 1,3-indandione (6 h). Yield 62 mg (43%). Dark-yellow crystals, mp 208–209 °C. ¹H NMR (500 MHz, DMSO-*d*₆) δ 7.60 (2H, t, J = 7.7 Hz, H Ph), 7.67 (1H, t, J = 7.4 Hz, H Ph), 7.70–7.78 (4H, m, H Ar), 7.80 (2H, d, J = 7.9 Hz, H Ph), 9.10 (2H, s, H-3', H-5'). ¹⁹F NMR (471 MHz, DMSO-*d*₆) δ 102.8 (s, CF₃). ¹³C NMR (126 MHz, DMSO-*d*₆) δ 107.2 (C-2), 113.4 (2C, q, J = 5.9 Hz, C-3', C-5'), 119.2 (2C, q, J = 275.2 Hz, CF₃), 121.3 (2C Ar), 128.5 (2C Ph), 130.0 (2C Ph), 131.6 (C Ph), 134.0 (2C Ar), 135.1 (C Ph), 138.9 (2C, q, J = 32.7 Hz, C-2', C-6'), 139.8 (2C Ar), 146.0 (C-4'), 191.0 (2C, CO). IR (ATR) ν 3101, 3065, 1693, 1648, 1518, 1319 (N–C), 1141 (CF₃). UV/vis (EtOH): λ_{\max} (ϵ_{\max}) = 437 (21948), 415 (15988), 246

(74128), 224 (151744). HRMS (ESI) m/z $[M + H]^+$. Calculated for $C_{22}H_{12}F_6NO_2$: 436.0772. Found: 436.0779.

3.6. Synthesis of Compounds 9

General Procedure

To a solution of trifluoroacetic acid (**2**) (100 mg, 0.56 mmol) in 1,4-dioxane (1 mL), a corresponding amine (1.17 mmol) was added with stirring. The reaction was monitored by TLC ($CHCl_3$:EtOH, 20:1). After completion, the reaction mixture was acidified with aqueous HCl (1 mL, 3 M). The precipitate was filtered and washed with water. The crude product was recrystallized from hexane.

6,6,6-Trifluoro-5-oxo-N-phenyl-3-(phenylamino)hex-3-enamide (9a). The reaction was carried out for 24 h. Yield 139 mg (72%), small yellow crystals, mp 135–137 °C. 1H NMR (500 MHz, $DMSO-d_6$) δ **Z-9a** (44%): 3.65 (2H, s, 2- CH_2), 5.79 (1H, s, 4-CH), 7.05 (2H, t, $J = 7.3$ Hz, H Ph), 7.30–7.34 (2H, m, H Ph), 7.40 (2H, d, $J = 7.5$ Hz, H Ph), 7.45 (4H, t, $J = 7.0$ Hz, H Ph), 10.08 (1H, s, NH amide), 12.56 (1H, s, NH enamine); **E-9a** (56%): 4.06 (2H, s, 2- CH_2), 5.59 (1H, s, 4-CH), 7.25–7.38 (6H, m, H Ph), 7.52 (2H, t, $J = 6.8$ Hz, H Ph), 7.61 (2H, d, $J = 7.4$ Hz, H Ph), 10.23 (1H, s, NH), 10.31 (1H, s, NH). ^{19}F NMR (376 MHz, $DMSO-d_6$) δ **Z-9a** (44%): 87.1 (s, CF_3); **E-9a** (56%): 86.6 (s, CF_3). ^{19}F NMR (376 MHz, $CDCl_3$) δ **Z-9a** (59%): 85.1 (s, CF_3); **E-9a** (41%): 84.8 (s, CF_3). ^{13}C NMR (101 MHz, $CDCl_3$) δ **Z-9a** (59%): 41.5 (CH_2), 91.3 (4-CH), 117.2 (q, $J = 288.3$ Hz, CF_3), 120.2 (2C Ph), 125.2 (C Ph), 125.9 (2C Ph), 128.3 (C Ph), 129.1 (2C Ph), 129.82 (2C Ph), 136.4 (C Ph), 136.9 (C Ph) 163.4 (1-CO), 164.0 (C-3), 177.8 (q, $J = 33.7$ Hz, 5-CO); **E-9a** (41%): 42.3 (CH_2), 88.7 (CH), 117.6 (q, $J = 290.2$ Hz, CF_3), 120.4 (2C Ph), 124.7 (2C Ph), 124.9 (C Ph), 127.8 (C Ph), 129.0 (2C Ph), 129.78 (2C Ph), 136.6 (C Ph), 137.5 (C Ph), 162.5 (1-CO), 166.3 (C-3), 178.5 (q, $J = 32.1$ Hz, 5-CO). IR (ATR) ν 3299, 3061, 3032, 1658 (C=O), 1578, 1242, 1172, 1116 (CF_3). Anal. Calculated for $C_{18}H_{15}F_3N_2O_2$: C 62.07; H 4.34; N 8.04. Found: C 61.81; H 4.12; N 7.94.

6,6,6-Trifluoro-N-(4-methoxyphenyl)-3-((4-methoxyphenyl)amino)-5-oxohex-3-enamide (9b). The reaction was carried out for 17 h. Yield 160 mg (69%), fine gray crystals, mp 163–165 °C. 1H NMR (400 MHz, $CDCl_3$) δ **Z-9b** (65%): 3.38 (2H, s, 2- CH_2), 3.79 (3H, s, OCH_3) 3.80 (3H, s, OCH_3), 5.68 (1H, s, 4-CH), 6.85 (2H, d, $J = 8.7$ Hz, H Ar), 6.91 (2H, d, $J = 8.6$ Hz, H Ar), 7.16 (1H, d, $J = 8.6$ Hz, H Ar), 7.29 (1H, d, $J = 8.7$ Hz, H Ar), 7.12 (1H, s, NH amide), 12.39 (1H, s, NH enamine); **E-9b** (35%): 3.79 (3H, s, OCH_3) 3.83 (3H, s, OCH_3), 4.00 (2H, s, 2- CH_2), 5.68 (1H, s, 4-CH), 6.84 (2H, d, $J = 8.7$ Hz, H Ar), 6.90 (2H, d, $J = 8.6$ Hz, H Ar), 7.11 (1H, d, $J = 8.6$ Hz, H Ar), 7.42 (1H, d, $J = 8.7$ Hz, H Ar), 8.74 (1H, s, NH amide), 9.63 (1H, s, NH enamine). ^{19}F NMR (376 MHz, $CDCl_3$) δ **Z-9b** (65%): 85.1 (s, CF_3); **E-9b** (35%): 84.9 (s, CF_3). ^{13}C NMR (126 MHz, $CDCl_3$) δ **Z-9b** (65%): 41.4 (CH_2), 55.47 (OCH_3), 55.52 (OCH_3), 90.9 (4-CH), 114.3 (2C Ar), 114.88 (2C Ar), 117.3 (q, $J = 288.6$ Hz, CF_3), 122.1 (2C Ar), 127.4 (2C Ar), 129.0 (C Ar), 129.9 (C Ar), 157.1 (C Ar), 159.4 (C Ar), 164.0, 164.2, 177.5 (q, $J = 33.6$ Hz, 5-CO); **E-9b** (35%): 42.0 (CH_2), 55.47 (OCH_3), 55.49 (OCH_3), 88.2 (4-CH), 114.1 (2C Ar), 114.91 (2C Ar), 117.7 (q, $J = 290.2$ Hz, CF_3), 122.0 (2C Ar), 126.4 (2C Ar), 129.3 (C Ar), 130.8 (C Ar), 156.7 (C Ar), 159.0 (C Ar), 163.2 (1-CO), 165.9 (C-3), 177.9 (q, $J = 31.3$ Hz, 5-CO). IR (ATR) ν 3282, 2999, 2842, 1651 (C=O), 1530, 1237, 1169, 1116 (CF_3). Anal. Calculated for $C_{20}H_{19}F_3N_2O_4 \cdot 0.25H_2O$: C 58.18; H 4.76; N 6.79. Found: C 58.25; H 4.48; N 6.54.

N-(4-Bromophenyl)-3-((4-bromophenyl)amino)-6,6,6-trifluoro-5-oxohex-3-enamide (9c). The reaction was carried out for 15 h. Yield 118 mg (41%), fine yellow crystals, mp 209–210 °C (decomp.). 1H NMR (500 MHz, $CDCl_3$) δ **Z-9c** (58%): 3.41 (2H, s, 2- CH_2), 5.70 (1H, s, 4-CH), 7.14 (2H, d, $J = 8.4$ Hz, H Ar), 7.31 (2H, d, $J = 8.6$ Hz, H Ar), 7.43 (1H, s, NH amide), 7.46 (2H, d, $J = 8.6$ Hz, H Ar), 7.54 (2H, d, $J = 8.4$ Hz, H Ar), 12.42 (1H, s, NH enamine); **E-9c** (42%): 3.98 (1H, s, 2- CH_2), 5.78 (1H, s, 4-CH), 7.09 (2H, d, $J = 8.5$ Hz, H Ar), 7.41–7.46 (4H, m, H Ar), 7.55 (2H, d, $J = 8.5$ Hz, H Ar), 8.32 (1H, s, NH amide), 9.62 (1H, s, NH enamine). ^{19}F NMR (471 MHz, $CDCl_3$) δ **Z-9c** (58%): 85.0 (s, CF_3); **E-9c** (42%): 84.8 (s, CF_3). IR (ATR) ν 3262, 3018, 3046, 1664 (C=O), 1589, 1533, 1246, 1111 (CF_3). Anal. Calculated for $C_{18}H_{13}Br_2F_3N_2O_2 \cdot 0.33H_2O$: C 42.22; H 2.69; N 5.47. Found: C 42.44; H 2.58; N 5.19.

N-Benzyl-3-(benzylamino)-6,6,6-trifluoro-5-oxohex-3-enamide (**9d**). The reaction was carried out for 17 h. Yield 51 mg (24%), colorless powder, mp 124–125 °C. ¹H NMR (500 MHz, DMSO-*d*₆) δ *Z*-**9d** (68%): 3.55 (2H, s, 2-CH₂), 4.30 (2H, d, *J* = 5.8 Hz, NCH₂), 4.72 (2H, d, *J* = 6.1 Hz, NCH₂), 5.50 (1H, s, 4-CH), 7.09–7.49 (10H, m, H Ph), 8.76 (1H, t, *J* = 5.8 Hz, NH amide), 11.29 (1H, t, *J* = 6.1 Hz, NH enamine); *E*-**9d** (32%): 3.84 (2H, s, 2-CH₂), 4.31 (2H, d, *J* = 6.0 Hz, NCH₂), 4.46 (2H, d, *J* = 5.6 Hz, NCH₂), 5.27 (1H, s, 4-CH), 7.09–7.49 (10H, m, H Ph), 8.45 (1H, t, *J* = 5.9 Hz, NH amide), 9.08 (1H, t, *J* = 5.8 Hz, NH enamine). ¹H NMR (500 MHz, CDCl₃) δ *Z*-**9d** (58%): 3.31 (2H, s, 2-CH₂), 4.39 (2H, d, *J* = 5.7 Hz, NCH₂), 4.61 (2H, d, *J* = 6.1 Hz, NCH₂), 5.44 (1H, s, 4-CH), 6.04 (1H, unres. t, NH) 7.20–7.40 (10H, m, H Ph), 11.32 (1H, unres. t, NH); *E*-**9d** (42%): 3.79 (2H, s, 2-CH₂), 4.32 (2H, d, *J* = 5.9 Hz, NCH₂), 4.33 (2H, d, *J* = 4.9 Hz, NCH₂), 5.41 (1H, s, 4-CH), 7.15 (2H, d, *J* = 7.0 Hz), 7.20–7.40 (8H, m), 7.90 (2H, unres. t, NH). ¹⁹F NMR (471 MHz, CDCl₃) δ *Z*-**9d** (58%): 85.1 (s, CF₃); *E*-**9d** (42%): 84.9 (s, CF₃). ¹³C NMR (126 MHz, CDCl₃) δ *Z*-**9d** (58%): 41.1 (2-CH₂), 44.0 (NCH₂), 48.0 (NCH₂), 90.1 (4-CH), 117.3 (q, *J* = 288.4 Hz), 127.1 (2C Ph), 127.8 (2C Ph), 127.9 (C Ph), 128.2 (C Ph), 128.9 (2C Ph), 129.2 (2C Ph), 135.7 (C Ph), 137.3 (C Ph), 164.9 (1-CO), 165.3 (C-3), 177.0 (q, *J* = 33.4 Hz, 5-CO). *E*-**9d** (42%): 40.5 (2-CH₂), 43.5 (NCH₂), 48.3 (NCH₂), 86.3 (4-CH), 117.7 (q, *J* = 290.5 Hz, CF₃), 127.2 (2C Ph), 127.4 (C Ph), 127.7 (2C Ph), 128.3 (C Ph), 128.6 (2C Ph), 129.1 (2C Ph), 134.8 (C Ph), 137.6 (C Ph), 163.5 (1-CO), 168.0 (C-3), 176.9 (q, *J* = 32.1 Hz, 5-CO). IR (ATR) ν 3308, 3062, 3033, 1641 (C=O), 1549, 1264, 1165, 1124 (CF₃). Anal. Calculated for C₂₀H₁₉F₃N₂O₂·0.33H₂O: C 62.82; H 5.18; N 7.33. Found: C 63.01; H 5.10; N 7.09.

N-Butyl-3-(butylamino)-6,6,6-trifluoro-5-oxohex-3-enamide (**9e**). The reaction was carried out for 72 h at 60 °C. Yield 12 mg (7%), large gray crystals, mp 79–80 °C. ¹H NMR (500 MHz, CDCl₃) δ *Z*-**9e** (65%): 0.93 (3H, t, *J* = 7.2 Hz, CH₃), 0.95 (3H, t, *J* = 7.2 Hz, CH₃), 1.32 (quint, 2H, *J* = 7.2 Hz, NCH₂CH₂), 1.43 (2H, sex, *J* = 7.2 Hz, CH₂CH₃), 1.49 (2H, sex, *J* = 7.2 Hz, CH₂CH₃), 1.63 (2H, quint, *J* = 7.2 Hz, NCH₂CH₂), 3.27 (2H, s, 2-CH₂), 3.28 (2H, q, *J* = 6.3 Hz, NCH₂), 3.42 (2H, q, *J* = 6.6 Hz, NCH₂), 5.36 (1H, s, 4-CH), 5.65 (1H, s, NH amide), 11.08 (1H, s, NH enamine); *E*-**9e** (35%): 0.90 (3H, t, *J* = 7.2 Hz, CH₃), 0.96 (3H, t, *J* = 7.2 Hz, CH₃), 1.34 (quint, 2H, *J* = 7.2 Hz, NCH₂CH₂), 1.39–1.53 (4H, masked, CH₂CH₃), 1.65 (2H, quint, *J* = 7.2 Hz, NCH₂CH₂), 3.15–3.24 (4H, m, NCH₂), 3.75 (2H, s, 2-CH₂), 5.32 (1H, s, 4-CH), 7.10 (1H, s, NH amide), 7.36 (1H, s, NH enamine). ¹⁹F NMR (471 MHz, CDCl₃) δ *Z*-**9e** (65%): 85.04 (s, CF₃); *E*-**9e** (35%): 84.90 (s, CF₃). IR (ATR) ν 3289, 2958, 2872, 1591 (C=O), 1548, 1306, 1184, 1114 (CF₃). HRMS (ESI) *m/z* [M + H]⁺. Calculated for C₁₄H₂₅F₃N₂O₂: 309.1790. Found: 309.1799.

3.7. Synthesis of Compound 10

1,3,4,5-Tetrahydro-4-(3,3,3-trifluoro-2-oxopropylidene)-2H-1,5-benzodiazepin-2-one (**10**). Benzene-1,2-diamine (63 mg, 0.58 mmol) was added to a solution of trifluoroacetic acid (**2**) (100 mg, 0.56 mmol) in 1,4-dioxane (1 mL) with stirring. The reaction was carried out for 24 h at room temperature. Then, the reaction mixture was acidified with aqueous HCl (1 mL, 3M). The precipitate was filtered and washed with water. The crude product was recrystallized from hexane. Yield 51 mg (33%), fine white powder, mp 244–245 °C (decomp.; lit. mp 243–245 °C [43]). ¹H NMR (500 MHz, CDCl₃) δ 3.31 (2H, s, CH₂), 5.68 (1H, s, CH), 7.12 (1H, dd, *J* = 7.6, 1.6 Hz, H Ar), 7.24–7.34 (3H, m, H Ar), 8.17 (1H, s, 1-NH), 12.57 (1H, s, 5-NH). ¹⁹F NMR (471 MHz, CDCl₃) δ 84.8 (s, CF₃). HRMS (ESI) *m/z* [M + H]⁺. Calculated for C₁₄H₂₅F₃N₂O₂: 271.0694. Found: 271.0673. The analytical data are in consistence with the literature [43].

3.8. Synthesis of Compounds 13 and 14

N'-Phenyl-2-(1-phenyl-5-(trifluoromethyl)-1H-pyrazol-3-yl)acetohydrazide (**13**) and *N'*-phenyl-2-(1-phenyl-3-(trifluoromethyl)-1H-pyrazol-5-yl)acetohydrazide (**14**). Phenylhydrazine (126 mg, 1.17 mmol) was added to a solution of trifluoroacetic acid (**2**) (100 mg, 0.56 mmol) in EtOH (1 mL) with stirring. The reaction was carried out for 24 h at room temperature. Then, the reaction mixture was acidified with aqueous HCl (1 mL, 3M). The precipitate

was filtered and washed with water. The crude product was recrystallized from hexane. Yield 122 mg (61%), yellow powder, mp 136–138 °C. The mixture of isomers **13** and **14** (82:18) did not separate by column chromatography. IR (ATR) ν 3281, 1657 (C=O), 1603, 1504, 1356, 1083 (CF₃). HRMS (ESI) m/z [M + H]⁺. Calculated for C₁₈H₁₆F₃N₄O: 361.1276. Found: 361.1276.

13: ¹H NMR (500 MHz, DMSO-*d*₆) δ *syn*-isomer (88%): 3.65 (2H, s, CH₂), 6.67–6.71 (1H, m, H Ph), 6.73 (2H, d, *J* = 7.8 Hz, H Ph), 7.03 (1H, s, H pyraz.), 7.11 (2H, t, *J* = 7.8 Hz, H Ph), 7.49–7.52 (2H, m, H Ph), 7.56–7.62 (3H, m, H Ph), 7.60–8.03 (br. s, 1H, PhNH), 9.91 (1H, s, CONH); *anti*-isomer (12%): 3.71 (2H, s, CH₂), 6.67–6.71 (2H, m, H Ph), 6.76 (1H, t, *J* = 7.3 Hz, H Ph), 6.95 (1H, s, H pyraz.), 7.18 (2H, t, *J* = 7.8 Hz, H Ph), 7.40–7.43 (2H, m, H Ph), 7.52–7.56 (3H, m, H Ph), 8.06 (1H, s, PhNH), 9.22 (1H, s, CONH). ¹⁹F NMR (471 MHz, DMSO-*d*₆) δ *anti*-isomer (12%): 106.18 (s, CF₃); *syn*-isomer (88%): 106.13 (s, CF₃). ¹³C NMR (126 MHz, CDCl₃) δ *syn*-isomer: 34.3 (CH₂), 109.0 (C-4 pyraz.), 113.5 (2C Ph), 119.4 (q, *J* = 269.4 Hz, CF₃), 121.3 (C Ph), 125.6 (2C Ph), 129.16 (2C Ph), 129.20 (2C Ph), 129.6 (C Ph), 133.9 (q, *J* = 39.7 Hz, C-5 pyraz.), 138.7 (C Ph), 146.2 (C Ph), 147.6 (C-3 pyraz.), 168.9 (CO); *anti*-isomer: most of the signals are masked due to low concentration.

14: ¹H NMR (500 MHz, DMSO-*d*₆) δ *syn*-isomer (71%): 3.78 (2H, s, CH₂), 6.55 (2H, d, *J* = 7.6 Hz, H Ph), 6.69 (1H, t, *J* = 7.4 Hz, H Ph), 6.87 (1H, s, H pyraz.), 7.10 (2H, t, *J* = 7.5 Hz, H Ph), 7.56–7.62 (5H, m, H Ph), 7.73 (1H, s, PhNH), 9.83 (1H, s, CONH); *anti*-isomer (29%): 3.79 (2H, s, CH₂), 6.56 (2H, d, *J* = 7.3 Hz, H Ph), 6.76 (1H, t, *J* = 7.3 Hz, H Ph), 6.83 (1H, s, H pyraz.), 7.14 (2H, t, *J* = 7.5 Hz, H Ph), 7.43–7.47 (2H, m, H Ph), 7.51–7.55 (3H, m, H Ph), 7.95 (1H, s, PhNH), 9.25 (1H, s, CONH). ¹⁹F NMR (471 MHz, DMSO-*d*₆) δ *anti*-isomer (29%): 101.91 (s, CF₃), *syn*-isomer (71%): 101.83 (s, CF₃). The analytical data are in consistence with the literature [35].

Supplementary Materials: The following supporting information can be downloaded at: <https://www.mdpi.com/article/10.3390/molecules27207098/s1>. Figure S1: UV/Vis spectra of compounds **5**; Table S1: Characteristic chemical shifts in ¹H, ¹³C, and ¹⁹F NMR spectra of compounds **3**; Table S2: Characteristic chemical shifts in ¹H, ¹³C, and ¹⁹F NMR spectra of compounds **5**; Table S3: Characteristic chemical shifts in ¹H, ¹³C, and ¹⁹F NMR spectra of *E*- and *Z*-isomers of enaminones **9**; full ¹H, ¹⁹F, and ¹³C NMR spectra of all synthesized compounds.

Author Contributions: Conceptualization and methodology were provided by V.Y.S., S.A.U. and D.L.O. conceived and designed the experiments. The experimental work was conducted by V.V.F. and S.A.U., S.A.U. and V.V.F. analyzed the results. S.A.U. studied and systemized the NMR data. S.A.U. and V.Y.S. wrote the paper. Project administration and funding acquisition were carried out by V.Y.S. and D.L.O. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by the Russian Science Foundation, grant number 18-13-00186 (<https://rscf.ru/project/18-13-00186/> accessed on 18 October 2022).

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Data are contained within the article and Supplementary Materials.

Acknowledgments: Analytical studies were carried out using equipment at the Center for Joint Use ‘Spectroscopy and Analysis of Organic Compounds’ at the Postovsky Institute of Organic Synthesis of the Russian Academy of Sciences (Ural Branch) and the Laboratory of Complex Investigations and Expert Evaluation of Organic Materials of the Center for Joint Use at the Ural Federal University.

Conflicts of Interest: The authors declare no conflict of interest.

Sample Availability: Samples of the compounds are not available from the authors.

References

1. McClacken, G.P.; Fairlamb, I.J.S. 2-Pyrone natural products and mimetics: Isolation, characterisation and biological activity. *Nat. Prod. Rep.* **2005**, *22*, 369–385. [[CrossRef](#)] [[PubMed](#)]
2. Goel, A.; Ram, V.J. Natural and synthetic 2H-pyran-2-ones and their versatility in organic synthesis. *Tetrahedron* **2009**, *65*, 7865–7913. [[CrossRef](#)]
3. Pratap, R.; Ram, V.J. 2H-Pyran-2-ones and their annelated analogs as multifaceted building blocks for the fabrication of diverse heterocycles. *Tetrahedron* **2017**, *73*, 2529–2590. [[CrossRef](#)]
4. Dobler, D.; Leitner, M.; Moor, N.; Reiser, O. 2-Pyrone—A privileged heterocycle and widespread motif in nature. *Eur. J. Org. Chem.* **2021**, *2021*, 6180–6205. [[CrossRef](#)]
5. Hickey, A.; Pardo, L.M.; Reen, F.J.; McClacken, G.P. Pyrones identified as LuxR signal molecules in photorhabdus and their synthetic analogues can alter multicellular phenotypic behavior of *Bacillus atropheaus*. *ACS Omega* **2021**, *6*, 33141–33148. [[CrossRef](#)]
6. Yadav, J.S.; Ganganna, B.; Dutta, P.; Singarapu, K.K. Synthesis and determination of absolute configuration of α -pyrones isolated from *Penicillium corylophilum*. *J. Org. Chem.* **2014**, *79*, 10762–10771. [[CrossRef](#)] [[PubMed](#)]
7. Lee, I.K.; Yun, B.S. Styrylpyrone-class compounds from medicinal fungi *Phellinus* and *Inonotus* spp., and their medicinal importance. *J. Antibiot.* **2011**, *64*, 349–359. [[CrossRef](#)] [[PubMed](#)]
8. Bhat, Z.S.; Rather, M.A.; Maqbool, M.; Lah, H.U.; Yousuf, S.K.; Ahmad, Z. α -pyrones: Small molecules with versatile structural diversity reflected in multiple pharmacological activities—an update. *Biomed. Pharmacother.* **2017**, *91*, 265–277. [[CrossRef](#)]
9. Aggarwal, R.; Walia, S.; Rani, C. Dehydroacetic acid and its derivatives as starting synthons for synthesis of heterocyclic compounds. *Heterocycles* **2017**, *94*, 1197–1244. [[CrossRef](#)]
10. Obydenov, D.L.; El-Tantawy, A.I.; Sosnovskikh, V.Y. Triacetic acid lactone as a bioprivileged molecule in organic synthesis. *Mendeleev Commun.* **2019**, *29*, 1–10. [[CrossRef](#)]
11. Prakash, O.; Kumar, A.; Singh, S.P. Synthesis of heterocyclic compounds from the reactions of dehydroacetic acid (DHA) and its derivatives. *Heterocycles* **2004**, *63*, 1193–1220. [[CrossRef](#)]
12. Moreno-Mañas, M.; Pleixats, R. Dehydroacetic acid, triacetic acid lactone, and related pyrones. *Adv. Heterocycl. Chem.* **1992**, *53*, 1–84. [[CrossRef](#)]
13. Politanskaya, L.V.; Selivanova, G.A.; Panteleeva, E.V.; Tretyakov, E.V.; Platonov, V.E.; Nikul'shin, P.V.; Vinogradov, A.S.; Zonov, Y.V.; Karpov, V.M.; Mezhenkova, T.V.; et al. Organofluorine chemistry: Promising growth areas and challenges. *Russ. Chem. Rev.* **2019**, *88*, 425–569. [[CrossRef](#)]
14. Han, J.; Remete, A.M.; Dobson, L.S.; Kiss, L.; Izawa, K.; Moriwaki, H.; Soloshonok, V.A.; O'Hagan, D. Next generation organofluorine containing blockbuster drugs. *J. Fluor. Chem.* **2020**, *239*, 109639. [[CrossRef](#)]
15. Isanbor, C.; O'Hagan, D. Fluorine in medicinal chemistry: A review of anti-cancer agents. *J. Fluor. Chem.* **2006**, *127*, 303–319. [[CrossRef](#)]
16. O'Hagan, D. Fluorine in health care: Organofluorine containing blockbuster drugs. *J. Fluor. Chem.* **2010**, *131*, 1071–1081. [[CrossRef](#)]
17. Purser, S.; Moore, P.R.; Swallow, S.; Gouverneur, V. Fluorine in medicinal chemistry. *Chem. Soc. Rev.* **2008**, *37*, 320–330. [[CrossRef](#)] [[PubMed](#)]
18. Wang, J.; Sánchez-Roselló, M.; Aceña, J.L.; del Pozo, C.; Sorochinsky, A.E.; Fustero, S.; Soloshonok, V.A.; Liu, H. Fluorine in pharmaceutical industry: Fluorine-containing drugs introduced to the market in the last decade (2001–2011). *Chem. Rev.* **2014**, *114*, 2432–2506. [[CrossRef](#)] [[PubMed](#)]
19. Fujiwara, T.; O'Hagan, D. Successful fluorine-containing herbicide agrochemicals. *J. Fluor. Chem.* **2014**, *167*, 16–29. [[CrossRef](#)]
20. Jeschke, P. The unique role of fluorine in the design of active ingredients for modern crop protection. *ChemBioChem* **2004**, *5*, 570–589. [[CrossRef](#)] [[PubMed](#)]
21. Berger, R.; Resnati, G.; Metrangolo, P.; Weber, E.; Hulliger, J. Organic fluorine compounds: A great opportunity for enhanced materials properties. *Chem. Soc. Rev.* **2011**, *40*, 3496–3508. [[CrossRef](#)] [[PubMed](#)]
22. Granqvist, L.; Virta, P. Characterization of G-quadruplex/hairpin transitions of RNAs by ^{19}F NMR spectroscopy. *Chem. Eur. J.* **2016**, *22*, 15360–15372. [[CrossRef](#)] [[PubMed](#)]
23. Marsh, E.N.G.; Suzuki, Y. Using ^{19}F NMR to probe biological interactions of proteins and peptides. *ACS Chem. Biol.* **2014**, *9*, 1242–1250. [[CrossRef](#)] [[PubMed](#)]
24. Resnick, P.R. Practical uses of fluorinated heterocycles. In *Fluorinated Heterocyclic Compounds*; John Wiley & Sons, Inc.: Hoboken, NJ, USA, 2009; pp. 493–506.
25. German, L.S.; Sterlin, S.R.; Cherstkov, V.F. Hexafluorodehydroacetic acid. *Bull. Acad. Sci. USSR Div. Chem. Sci.* **1982**, *31*, 1476–1477. [[CrossRef](#)]
26. Li, C.-S.; Lau, C.K.; Therien, M.; Prasit, P. Pyrones as Inhibitors of Cyclooxygenase-2. U.S. Patent 0058690, 16 May 2002.
27. Hanselmann, P.; Wenger, W. Method for the Production of 6,6,6-Trihalo-3,5-dioxohexanoic Acid Esters. WO Patent 040087, 6 May 2005.
28. Garratt, S. The Mechanism of the reaction between dehydroacetic acid and alkylamines. *J. Org. Chem.* **1963**, *28*, 1886–1888. [[CrossRef](#)]
29. Cook, D. The preparation, properties, and structure of 2,6-bis-(alkylamino)-2,5-heptadien-4-ones. *Can. J. Chem.* **1963**, *41*, 1435–1440. [[CrossRef](#)]

30. Pierce, J.B.; Ariyan, Z.S.; Ovenden, G.S. Preparation and antiinflammatory activity of 2- and 4-pyridones. *J. Med. Chem.* **1982**, *25*, 131–136. [[CrossRef](#)]
31. Schmidt, R.; Stolte, M.; Grüne, M.; Würthner, F. Hydrogen-bond-directed formation of supramolecular polymers incorporating head-to-tail oriented dipolar merocyanine dyes. *Macromolecules* **2011**, *44*, 3766–3776. [[CrossRef](#)]
32. Würthner, F.; Schmidt, J.; Stolte, M.; Wortmann, R. Hydrogen-bond-directed head-to-tail orientation of dipolar merocyanine dyes: A strategy for the design of electrooptical materials. *Angew. Chem. Int. Ed.* **2006**, *45*, 3842–3846. [[CrossRef](#)] [[PubMed](#)]
33. Eiden, F. Untersuchungen an γ -Pyronen. 4. Mitteilung: Die Kondensation von γ -Pyronen mit cyclischen Malonsäureamiden. *Arch. Pharm.* **1960**, *293*, 404–414. [[CrossRef](#)] [[PubMed](#)]
34. Obydenov, D.L.; El-Tantawy, A.I.; Sosnovskikh, V.Y. Bio-based triacetic acid lactone in the synthesis of azaheterocycles via a ring-opening transformation. *New J. Chem.* **2018**, *42*, 8943–8952. [[CrossRef](#)]
35. Usachev, B.I.; Obydenov, D.L.; Rösenthaller, G.-V.; Sosnovskikh, V.Y. 2-Cyano-6-(trifluoromethyl)-4H-pyran-4-one: A novel versatile CF₃-containing building block. *J. Fluor. Chem.* **2012**, *137*, 22–26. [[CrossRef](#)]
36. Zheglova, D.K.; Genov, D.G.; Gribanov, A.V.; Kol'tsov, A.I.; Smirnov, S.N. NMR spectroscopic study of the (Z)/(E)-isomerism of 1-aryl-3-arylamino-2-propen-1-ones in solution and in the crystalline state. *Monatsh. Chem.* **1994**, *125*, 1443–1446. [[CrossRef](#)]
37. Gerus, I.I.; Balabon, O.A.; Pazenok, S.V.; Lui, N.; Kondratov, I.S.; Tarasenko, K.V.; Shaitanova, E.N.; Ivasyshyn, V.E.; Kukhar, V.P. Synthesis and properties of polyfunctional cyclic β -alkoxy- α,β -unsaturated ketones based on 4-methylene-1,3-dioxolanes. *Eur. J. Org. Chem.* **2018**, *2018*, 3853–3861. [[CrossRef](#)]
38. Wójcik, J.; Domalewski, W.; Kamieńska-Trela, K.; Stefaniak, L.; Vdovienko, S.I.; Gerus, I.I.; Gorbunova, M.G. Conformational behaviour of some trifluoroenaminones by multinuclear magnetic resonance. *Magn. Reson. Chem.* **1993**, *31*, 808–814. [[CrossRef](#)]
39. Kiang, A.K.; Tan, S.F.; Wong, W.S. Reactions of acetonedicarboxylic anhydride (tetrahydropyrantrione) and its mono- and di-acetyl derivatives with amines. *J. Chem. Soc. C* **1971**, 2721–2726. [[CrossRef](#)]
40. Usachev, S.A.; Usachev, B.I.; Sosnovskikh, V.Y. Synthesis of 6-hydroxy-5,6-dihydro-2-pyrones and -pyridones by reaction of 4-aryl-6-trifluoromethyl-2-pyrones with water, hydrazine, and hydroxylamine. *Chem. Heterocycl. Compd.* **2017**, *53*, 1294–1301. [[CrossRef](#)]
41. Gerus, I.I.; Tolmachova, N.A.; Vdovenko, S.I.; Fröhlich, R.; Haufe, G. A convenient synthesis and chemical properties of 3-acylamino-6-poly-fluoroalkyl-2H-pyran-2-ones. *Synthesis* **2005**, *2005*, 1269–1278. [[CrossRef](#)]
42. Ye, W.-P.; Mu, H.-L.; Shi, X.-C.; Cheng, Y.-X.; Li, Y.-S. Synthesis and characterization of the titanium complexes bearing two regioisomeric trifluoromethyl-containing enaminketonato ligands and their behavior in ethylene polymerization. *Dalt. Trans.* **2009**, *2009*, 9452–9465. [[CrossRef](#)] [[PubMed](#)]
43. Desens, W.; Winterberg, M.; Michalik, D.; Langer, P. Synthesis and solution structure of 1H-benzo-1,5-diazepine derivatives with a perfluoroalkyl side chain. *Helv. Chim. Acta* **2016**, *99*, 361–372. [[CrossRef](#)]